Sharp is investing $20 million to expand autoinjector and pen device assembly at its facility in Macungie, Pennsylvania, as demand for injectable therapies continues to accelerate worldwide.

The company said the funding will establish two dedicated assembly lines to support both clinical and commercial programmes. A semi-manual line will handle smaller runs of custom and non-custom devices at around two units per minute, while a mid-speed line capable of assembling 50–70 devices per minute will feature inline labelling and cartoning. The facility will support widely used platforms including Ypsomed’s YpsoMate and SHL Medical’s Molly autoinjectors.

The investment reflects wider market dynamics. Analysts forecast the global autoinjector market will reach $20.6 billion by 2030, expanding at a compound annual growth rate of 15%. Growth is being fuelled by increased use of biologics across chronic conditions, the widespread adoption of self-administration devices, and surging demand for obesity management drugs such as GLP-1 receptor agonists. Demand is also rising for emergency-use injectables, where speed and reliability of delivery can be critical.

Jeff Benedict, chief commercial officer at Sharp, said: “Pharma organisations are increasingly choosing injectables in advanced delivery systems that ensure reliable and safe drug administration, especially in critical or emergency scenarios. The rapid rise in demand for obesity management products, coupled with the market requirement for more sustainable solutions, has fuelled innovation and unlocked new possibilities in this space.”

The Macungie expansion builds on Sharp’s earlier work in Europe, where its Hamont-Achel, Belgium, facility already supports autoinjector assembly for clinical and commercial programmes. The new US production lines are expected to be fully operational in the first half of 2027 and will allow Sharp to scale its support for global partners across a wider range of therapeutic areas.

Benedict added: “Our new US production lines will position Sharp to support the global market. Sharp’s expertise in autoinjector packaging, combined with our international network, gives us a strong base to deliver solutions for emerging therapies.”

Sharp operates nine GMP facilities across the US, UK and Europe, providing sterile manufacturing, clinical trial services and commercial packaging.